-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on Definium Therapeutics, Maintains $66 Price Target

Benzinga·09/11/2026 13:49:01
語音播報
RBC Capital analyst Brian Abrahams reiterates Definium Therapeutics (NASDAQ:DFTX) with a Outperform and maintains $66 price target.